Point-of-Care-Testing in Acute Stroke Management: An Unmet Need Ripe for Technological Harvest
Open Access
- 3 August 2017
- journal article
- review article
- Published by MDPI AG in Biosensors
- Vol. 7 (3), 30
- https://doi.org/10.3390/bios7030030
Abstract
Stroke, the second highest leading cause of death, is caused by an abrupt interruption of blood to the brain. Supply of blood needs to be promptly restored to salvage brain tissues from irreversible neuronal death. Existing assessment of stroke patients is based largely on detailed clinical evaluation that is complemented by neuroimaging methods. However, emerging data point to the potential use of blood-derived biomarkers in aiding clinical decision-making especially in the diagnosis of ischemic stroke, triaging patients for acute reperfusion therapies, and in informing stroke mechanisms and prognosis. The demand for newer techniques to deliver individualized information on-site for incorporation into a time-sensitive work-flow has become greater. In this review, we examine the roles of a portable and easy to use point-of-care-test (POCT) in shortening the time-to-treatment, classifying stroke subtypes and improving patient’s outcome. We first examine the conventional stroke management workflow, then highlight situations where a bedside biomarker assessment might aid clinical decision-making. A novel stroke POCT approach is presented, which combines the use of quantitative and multiplex POCT platforms for the detection of specific stroke biomarkers, as well as data-mining tools to drive analytical processes. Further work is needed in the development of POCTs to fulfill an unmet need in acute stroke management.Keywords
This publication has 254 references indexed in Scilit:
- The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialThe Lancet, 2012
- Proteolysis of Submembrane Cytoskeletal Proteins Ankyrin‐G and αII‐Spectrin Following Diffuse Brain Injury: A Role in White Matter Vulnerability at Nodes of RanvierBrain Pathology, 2010
- Time-critical neurological emergencies: the unfulfilled role for point-of-care testingInternational Journal of Emergency Medicine, 2010
- Ubiquitin C‐terminal hydrolase‐L1 as a biomarker for ischemic and traumatic brain injury in ratsEuropean Journal of Neuroscience, 2010
- Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury*Critical Care Medicine, 2010
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Dicyclomine, an M1 Muscarinic Antagonist, Reduces Biomarker Levels, But Not Neuronal Degeneration, in Fluid Percussion Brain InjuryJournal of Neurotrauma, 2008
- Reliability of fMRI for studies of language in post-stroke aphasia subjectsNeuroImage, 2008
- Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparisonThe Lancet, 2007
- GFAP Versus S100B in Serum after Traumatic Brain Injury: Relationship to Brain Damage and OutcomeJournal of Neurotrauma, 2004